应用68Ga-PSMA-11 PET/CT评估转移性去势抵抗性前列腺癌患者的治疗反应:EAU/EANM推荐意见在临床实践中的应用
该回顾性研究纳入18例起始新型内分泌药物治疗的mCRPC患者,比较68Ga-PSMA-11 PET/CT与传统影像的治疗反应评估,并分析治疗4周与12周PET/CT参数的一致性;PET/CT可评估率89%高于传统影像61%,W4与W12结果高度一致(κ=0.74),但2例因闪烁现象被误判为进展。
要点
- 68Ga-PSMA-11 PET/CT在mCRPC患者治疗反应评估中可评估率89%,高于传统影像的61%。
- 治疗4周与12周PET/CT反应评估结果高度一致(κ=0.74),但4周评估需警惕闪烁现象。
- 2例(13%)因PSMA PET/CT闪烁现象在4周被误判为进展,该现象在12周消失。
核心结论
- 68Ga-PSMA-11 PET/CT体积评估可改善接受新型内分泌药物治疗的mCRPC患者的治疗反应评估;4周早期评估因闪烁现象需谨慎,4周与12周PET/CT反应评估结果高度一致,需进一步研究以区分4周时的进展与闪烁现象并帮助理解治疗耐药。
研究设计与样本
- 回顾性纳入18例起始新型内分泌药物治疗的mCRPC患者,在治疗前(基线)、第4周和第12周行68Ga-PSMA-11 PET/CT,并在基线和第12周行传统影像(骨显像、CT)。
诊断标准与关键数值
- 根据68Ga-PSMA-11 PET/CT、前列腺特异性抗原和传统影像标准将患者分为无进展性疾病或进展性疾病;PET/CT图像定量分析最大SUV、平均SUV和PSMA配体阳性病灶总数;68Ga-PSMA-11 PET/CT在16/18例(89%)可评估治疗反应,传统影像在11/18例(61%)可评估;W4与W12的68Ga-PSMA-11 PET/CT结果一致性κ=0.74。
临床应用与阅片要点
- 作者认为,68Ga-PSMA-11 PET/CT体积评估可改善接受新型内分泌药物治疗的mCRPC患者的治疗反应评估;作者指出,由于闪烁现象,第4周早期反应评估需谨慎。
局限性
- 原文结论指出这些发现需进一步研究,以区分第4周时的进展性疾病与闪烁现象,并帮助理解治疗耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
For patients with metastatic castration-resistant prostate cancer (mCRPC), no reliable biomarkers for predicting therapeutic response or assisting in treatment selection and sequencing are currently available. Using the recent European Association of Urology and European Association of Nuclear Medicine recommendations, we aimed to compare response assessment between prostate-specific membrane antigen (PSMA) PET/CT and conventional imaging in mCRPC patients starting first-line treatment with a novel hormonal agent (NHA) and to perform a sequential comparative analysis of PSMA PET/CT-derived parameters after 4 and 12 wk of therapy. Methods: Data from 18 mCRPC patients who started NHA treatment and underwent 68Ga-PSMA-11 PET/CT before therapy initiation (baseline), at week 4 (W4), and at week 12 (W12) in addition to conventional imaging (bone scintigraphy, CT) at baseline and W12 were retrospectively included. PET/CT images were quantitatively analyzed for maximum and mean SUV and total PSMA ligand-positive lesions. Comparative analysis of PET/CT-derived parameters was performed, and patients were classified as having nonprogressive disease or progressive disease (PD) according to 68Ga-PSMA-11 PET/CT, prostate-specific antigen, and conventional imaging criteria. Results: Treatment response was evaluable by 68Ga-PSMA-11 PET/CT in 16 of 18 patients (89%) and by conventional imaging in 11 of 18 patients (61%). Five of 16 patients classified as having PD by 68Ga-PSMA-11 PET/CT at W12 had already met progression criteria at W4, and substantial agreement was observed between W4 and W12 (κ, 0.74) 68Ga-PSMA-11 PET/CT results. Nonetheless, 2 of 16 patients (13%) were incorrectly classified as having PD because of a flare phenomenon on PSMA PET/CT that disappeared at W12. Conclusion: Volumetric assessments of 68Ga-PSMA-11 PET/CT imaging can improve response evaluation in NHA-treated patients with mCRPC. Although early response assessments at W4 need to be approached with caution because of flare, 68Ga-PSMA-11 PET/CT imaging at W4 and W12 revealed substantial agreement in therapy response assessments; these findings warrant further investigation to distinguish PD from flare at W4 and help improve the understanding of resistance to therapy.
引用
- Denis, Cousin, Laere, et al. Using 68Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical Practice. J Nucl Med. 2022. PMID: 35450960. doi:10.2967/jnumed.121.263611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。